Details of the filing
Hims & Hers Health Inc saw its share price decline 5.3% on Tuesday following the filing of a Form 144. The filing shows that Oluyemi Okupe, the company’s chief financial officer, intends to sell 240,560 shares through Goldman Sachs & Co. LLC. The aggregate market value of the proposed disposition is approximately $4.9 million and the proposed sale date listed in the filing is April 6, 2026.
How the shares were acquired and trading plan
The Form 144 states the shares in question were obtained through a mix of compensation mechanisms, including stock options and restricted stock units, over the period from February 2022 through March 2026. The filing also notes that the sales are to be conducted under a Rule 10b5-1 trading plan dated May 21, 2025.
Recent insider activity
The document reports that Okupe sold company shares on several occasions during the past three months. Transactions listed in the filing occurred on January 5, January 20, February 3, March 20, and April 6, 2026. Those prior sales generated gross proceeds that ranged from approximately $20,000 to $151,000 per individual transaction.
Company context and market reaction
At the time the filing was made public, Hims & Hers had 219,561,143 shares outstanding. The company, based in San Francisco, California, has experienced notable equity depreciation recently, with its share price down 30.8% over the past year. The Form 144 disclosure and the proposed sale were followed by the reported intraday share-price decline.
Regulatory mechanics
Form 144 filings are required when insiders intend to sell restricted or control securities under Rule 144 of the Securities Act of 1933. Such filings frequently attract investor attention because they reveal insider dispositions. The filing in this case specifies that the transactions are being executed under a pre-established Rule 10b5-1 plan, a structure often treated as routine portfolio management when assessing insider sales.
What this report does not claim
The filing records and the market reaction are set out above. No additional explanations, motives, or future outcomes are asserted beyond the information contained in the Form 144 and the trading-plan disclosure.